|Bid||2.830 x 1100|
|Ask||2.840 x 900|
|Day's Range||2.6500 - 2.8800|
|52 Week Range||2.0010 - 8.4000|
|Beta (3Y Monthly)||2.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.58|
Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Dec. 4, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...
CELEBRATION, Fla., Dec. 3, 2018 /PRNewswire/ -- KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., will present live at VirtualInvestorConferences.com on December 6, 2018.
A look at the shareholders of KemPharm Inc (NASDAQ:KMPH) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the addition of a new product candidate, KP879, which the company plans to develop as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD). Based on current timelines, KemPharm expects to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for KP879 as early as the end of 2018.
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced positive topline results from KP415.E01.
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 8, 2018, 4:30 p.m. ET CORALVILLE, Iowa, Nov. 01, 2018 -- KemPharm, Inc..
KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs today announced its entry into a definitive collaboration and license agreement with KVK Tech, Inc. for the U.S. commercial rights of its FDA-approved prodrug product, APADAZ (benzhydrocodone and acetaminophen tablets). Under the terms of the agreement, KemPharm is eligible to receive up to an estimated $3.4 million in pre-launch payments and certain cost reimbursements, including a $2.0 million payment upon achievement of a specified milestone related to the initial formulary adoption of APADAZ, as well as an aggregate of up to $53 million in milestone payments tied to specific net sales levels. In addition, net profits will be shared between KemPharm and KVK up to 50% based on achieving specified net sales levels.
CORALVILLE, Iowa, Oct. 24, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today.
Drug Development Approach Combines twoXAR’s Artificial-Intelligence-Driven Drug Discovery Technology with KemPharm’s LATTM Prodrug Technology CORALVILLE, Iowa, Oct. 23, 2018.
Event Held Today, October 11, 2018 CORALVILLE, Iowa, Oct. 11, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and.
Shares of Aytu BioScience Inc. plummeted 33% and of KemPharm Inc. plunged 32% Friday, to pace the Nasdaq's decliners, as both specialty pharmaceutical companies announced relatively large public share offerings that priced at deep discounts. KemPharm offered 8.33 million shares, representing 52% of the shares outstanding, that priced at $3.00 a share, or 28% below Thursday's closing price of $4.18. Meanwhile, Aytu offered 457,007 shares of common stock, 8.34 million shares of preferred stock convertible into 8.34 million shares of common stock at a conversion price of $1.50 per share, and warrants to buy and additional 8 million shares of common stock at an exercise price of $1.50 a share. That price was 26% below Thursday's closing price of $2.02. Aytu had 1.80 million shares outstanding as of Aug. 31. KemPharm shares have now lost 56% over the past three months and Aytu's stock has dropped 75%, while the S&P 500 has gained 6.1%.
KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by KemPharm. In addition, KemPharm intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Event to be Webcast Live on Thursday, October 11, 2018, at 8:30 a.m. ET CORALVILLE, Iowa, Oct. 03, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company.
KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced topline results from its intranasal (IN) human abuse potential (HAP) clinical trial of serdexmethylphenidate (SDX, a prodrug of d-methylphenidate, or KP415 Prodrug), the major active pharmaceutical ingredient (API) in KP415, KemPharm’s investigational product candidate for the treatment of ADHD. In the IN HAP trial (KP415.A02), SDX produced significantly lower scores on the primary endpoint, maximal Drug Liking (Emax), and other abuse-related endpoints, compared to intranasal d-methylphenidate hydrochloride, indicating that SDX is not efficiently converted to active d-methylphenidate when snorted.
KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.